Abstracts tagged "glucocorticoids"

Abstract Number: 2421 • ACR Convergence 2024
Trends in Glucocorticoid Use in Systemic Lupus Erythematosus in a Population-Based Inception Cohort from 1976 to 2018: The Lupus Midwest Network
Mariana Gonzalez-Trevino¹, Jaime Flores Gouyonnet¹, Qiping Xu², Cassondra Hulshizer³, Jose Meade-Aguilar⁴, Erika Navarro-Mendoza¹, Mario Bautista-Vargas⁵, Gabriel Figueroa-Parra⁶, Alain Sanchez-Rodriguez⁷, Maria Cuellar-Gutierrez¹, Andrew C. Hanson⁸, Cynthia Crowson¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Health System - Mankato, Mankato, MN, ³Mayo Clinic, Utica, MN, ⁴Boston University/Boston Medical Center, Boston, MA, ⁵Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁷Mayo Clinic College of Medicine and Science, Rochester, MN, ⁸Mayo Clinic, Rochester
Background/Purpose: We examined the patterns of glucocorticoid (GC) use and the temporal trends of GC initiation, discontinuation, and reduction over four decades in a population-based…
Abstract Number: 2673 • ACR Convergence 2024
Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis
Diane Lacaille¹, Coraline Danieli², Kasra Moolooghy¹ and Michal Abrahamowicz³, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC, Canada, ³McGill University, Verdun, Canada
Background/Purpose: Glucocorticosteroid (GC) use is associated with increased mortality risk, especially from cardiovascular diseases (CVD) and infections, with dose and duration of use influencing risk.…
Abstract Number: 0975 • ACR Convergence 2024
Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica
Sebastian E. Sattui¹, FRANK HARTMUT DR. BUTTGEREIT², Merav Lidar³, Kerri Ford⁴, Stefano Fiore⁵, Lita Araujo⁴, Timothy Beukelman⁶, Fenglong Xie⁷ and Jeffrey Curtis⁸, ¹University of Pittsburgh, Pittsburgh, PA, ²Charité University Medicine Berlin, Berlin, Germany, ³Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Israel, ⁴Sanofi, Cambridge, MA, ⁵Sanofi, Bridgewater, NJ, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: PMR, a common inflammatory rheumatic disease in older adults, is primarily treated with glucocorticoids (GC). A high comorbidity burden in PMR may increase the…
Abstract Number: 1719 • ACR Convergence 2024
Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study
Beth Wallace¹, Yuqing Gao², H. Myra Kim³, Bryant England⁴, Sauer brian⁵, grant Cannon⁶, Punyasha Roul⁷, Ted Mikuls⁴, Shirley Cohen-Mekelburg⁸, Daniel Clauw⁹, Wyndy Wiitala², Rodney Hayward¹⁰, Jeremy Sussman¹¹ and Akbar Waljee¹¹, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³University of Michigan School of Public Health, Ann Arbor, MI, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸University of Michigan Department of Internal Medicine, Division of Gastroenterology, Ann Arbor, MI, ⁹University of Michigan, Whitmore Lake, MI, ¹⁰Department of Internal Medicine, University of Michigan; Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI, ¹¹Internal Medicine and Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Our work presented previously suggests recent GC use (up to 2 years prior…
Abstract Number: 2431 • ACR Convergence 2024
DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use
doria Andrea¹, Ronald Van Vollenhoven², Eric Morand³, Catharina Lindholm⁴, Jonatan Hedberg⁴, Miina Waratani⁵ and Danuta Kielar⁶, ¹University of Padova, Padova, Italy, ²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ⁴BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁵Biopharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁶Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: 2023 EULAR recommendations for the management of SLE open up the option for early treatment initiation with biologics without the requirement to fail immunosuppressants/DMARDs…
Abstract Number: 1124 • ACR Convergence 2024
Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids
Xiaodi Ruan¹, Michael Williams², Gul Karakoc¹, Elizabeth McNeer¹, Leena Choi¹, Jonathan D. Mosley¹, C. Michael Stein¹ and Vivian K. Kawai¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²VUMC, Nashville, TN
Background/Purpose: Glucocorticoids (GCs) are potent anti-inflammatory drugs that are commonly prescribed, particularly for rheumatic and immunologic conditions. Hyperglycemia is an important adverse effect and occurs…
Abstract Number: 1799 • ACR Convergence 2024
In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus
Jia Xin Chow¹, Rochelle Sherlock², Taylah Bennett², Eric Morand³ and Sarah Jones², ¹Monash University, Melbourne, Victoria, Australia, ²Monash University, Melbourne, Australia, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: The strategy of inhibiting toll-like receptors (TLR) 7 and 8 is being evaluated in clinical trials in systemic lupus erythematosus (SLE) to assess its…
Abstract Number: 2432 • ACR Convergence 2024
In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist
Shailesh Dudhgaonkar¹, Siva Subramani², Puneet Chopra², Anjuman Rudra², Sourabha Palachandra², Nikita Sanjay Bhatt², Veeresh Pabbala², Sabariya Selvam², Mobeen Shaik², Amit Anand², Benjamin King³, Kristina Chadwick³, Alaric Dyckman³, Qihong Zhao³, Frédéric Baribaud³, Ramya Janardhana⁴ and Vineeta Shobha⁵, ¹Bristol Myers Squibb, Bangalore, India, ²Biocon BMS Research Center, Syngene International Ltd, Bangalore, India, ³Bristol Myers Squibb, Princeton, NJ, ⁴St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁵St. John’s Hospital, Bangalore, India
Background/Purpose: SLE is a highly heterogeneous chronic autoimmune disease, with glucocorticoid therapy as the standard of care. SLE control requires high steroid doses; long-term use…
Abstract Number: 1126 • ACR Convergence 2024
The Outcomes of Carpal Tunnel Injections and Carpal Tunnel Surgery
wilmer sibbitt¹, dihowm Fatma¹, N. SUZANNE Emil¹, Maheswari Muruganandam², Roderick A Fields¹, Vangala Adarsh¹, Frank O'Sullivan³, Shuhei Hattori⁴, Frank M Delgado¹ and Krystle Tapia¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM, ⁴University of Hawaii, Hawaii
Background/Purpose: arpal tunnel syndrome (CTS) is the most common peripheral neuropathy secondary to chronic median nerve compression at the wrist within the space-limited carpal tunnel…
Abstract Number: 1983 • ACR Convergence 2024
Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review
Aaron Teel¹, Adrian Grebowicz², Mats Junek³, Stephanie Garner⁴, Tom Appleton⁵ and Faiza Khokhar⁶, ¹London Health Sciences Centre, Sarnia, ON, Canada, ²Western University, London, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵The University of Western Ontario, London, ON, Canada, ⁶McMaster University, St. Joseph's Hamilton, Mississauga, ON, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy that have been associated with immune-related adverse events (irAEs). These include multiple rheumatic diseases…
Abstract Number: 2435 • ACR Convergence 2024
Attainment of Remission, Use of Immunomodulatory/suppressive Agents and Gradual Dose Tapering May Facilitate Flare-free Withdrawal of Glucocorticoids in Patients with Systemic Lupus Erythematosus
Spyridon Katechis¹, Sofia Pitsigavdaki², Myrto Nikoloudaki², Panagiotis Garantziotis³, Ettore Silvagni⁴, Argyro Repa², Antonio Marangoni⁵, Irini Flouri⁶, Nestor Avgoustidis⁷, Konstantinos Parperis⁸, Marcello Govoni⁵, Prodromos Sidiropoulos⁹, Dimitrios Boumpas¹⁰, Antonios Fanouriakis¹, George Bertsias² and Alessandra Bortoluzzi⁵, ¹Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ²Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, ³Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁴Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy, Ferrara, ⁵Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy, Ferrara, Italy, ⁶Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklio, Crete, Greece, ⁷University Hospital, Rheumatology and Clinical Immunology,, Heraklion, Greece, ⁸University of Cyprus Medical School, Nicosia, Cyprus, ⁹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece, ¹⁰4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece
Background/Purpose: For patients with SLE who are treated with glucocorticoids (GC), discontinuation of the latter is an important goal. However, the clinical conditions under which…
Abstract Number: 1246 • ACR Convergence 2024
Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies
Alessandro Giollo¹, Mariangela Salvato², Margherita Zen³ and doria Andrea⁴, ¹Azienda Ospedale Università Padova, Padova, Padua, Italy, ²University of Padua, Padova, Italy, ³University of Padova, Padova, Padua, Italy, ⁴University of Padova, Padova, Italy
Background/Purpose: To explore the influence of the rheumatologist's sex on long-term outcomes in patients with rheumatoid arthritis (RA) undergoing biologic therapy.Methods: This is a prospective,…
Abstract Number: 1989 • ACR Convergence 2024
Higher Early Cumulative Glucocorticoid Exposure Is Associated with Worse Progression-Free Survival in Patients with Immune Checkpoint Inhibitor Inflammatory Arthritis
Minerva Nong¹, Deanna Jannat-Khah², Karmela Kim Chan², Nilasha Ghosh³ and Anne Bass⁴, ¹Hospital for Special Surgery, Tampa, FL, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Although immune checkpoint inhibitors (ICI) have transformed cancer treatment, they unleash a range of immune-related adverse events (irAE), including inflammatory arthritis (ICI-IA). Glucocorticoids are…
Abstract Number: 2438 • ACR Convergence 2024
Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus
Vasileios Kyttaris¹, Gelareh Atefi², Dan Persons³, Dana Withrow³ and Mawuena Binka⁴, ¹BIDMC, Boston, MA, ²AstraZeneca, Media, PA, ³Trio Health, Louisville, CO, USA, Louisville, ⁴BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE
Background/Purpose: Oral corticosteroids (OCS) are a mainstay in the clinical management of systemic lupus erythematosus (SLE). However, prolonged use may result in systemic side effects.1…
Abstract Number: 1273 • ACR Convergence 2024
An Investigation of Traumatic Events and Mental Health in cSLE
Paris Moaf¹, Ashley Danguecan², Michelle Quilter³, Julie Couture⁴, Daniela Dominguez⁵, Lawrence Ng⁶, Asha Jeyanathan⁷, Reva Schachter⁸, Daphne Korczak⁹, Deborah Levy⁶, Linda Hiraki⁶ and Andrea Knight¹⁰, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ³Whyteman’s Brae Hospital, Kirkcaldy, United Kingdom, ⁴Centre mère-enfant Soleil du CHU de Québec, Québec, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁸Sickkids Toronto, Toronto, ON, Canada, ⁹Hospital for Sick Children, University of toronto, Toronto, ON, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with substantial morbidity, particularly in childhood-onset SLE (cSLE). Mental health conditions such as depression and…

« Previous Page
1
…
4
5
6
7
8
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].